COVID-19 Vaccines Safety Tracking (CoVaST)

Summary

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

Conditions

• Adverse Reaction to Vaccine
• COVID19 Vaccine

Interventions

BIOLOGICAL

BNT162b2

Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

BIOLOGICAL

mRNA-1273

Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

BIOLOGICAL

AZD1222

Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)

BIOLOGICAL

CoronaVac

Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

BIOLOGICAL

Sinopharm

Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

BIOLOGICAL

Gam-COVID-Vac

Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

BIOLOGICAL

JNJ-78436735

Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

BIOLOGICAL

CVnCoV

Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

BIOLOGICAL

NVX-CoV2373

Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

BIOLOGICAL

BBV152

Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)

Sponsors & Collaborators

• Masaryk University

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2025-12-31

Completion

2026-12-31

FDA Drug

Yes

Countries

• United States
• Canada
• Croatia
• Czechia
• Estonia
• Ethiopia
• Germany
• Ghana
• Mexico
• Poland
• Portugal
• Russia
• Serbia
• Slovenia

Study Locations